Carestream Health ships DRX-1Aposense imaging agent detects early cell death
Chindex International will sell advanced visualization software from Vital Images as part of its China portfolio. Chindex provides healthcare services and medical products to China-based hospitals and clinics, including more than 750 Level 1 trauma centers. Vital Images' software processes CT and MR data into 2D and volumetric images.
Wireless, cassette-size digital radiography detectors have begun shipping from Carestream Health as the company fills orders placed several months ago from countries around the world for its new DRX-1. The wireless detector is designed for radiographic exams, including those in general radiology, trauma, and orthopedics. The DRX-1 system minimizes installation costs by integrating this detector with a console, thereby requiring no modifications to existing analog equipment.
Whether radiation therapy is having the desired effect on brain tumors may be seen with the use of a PET imaging agent, according to data presented last week at the SNM meeting. The PET tracer, F-18 ML-10, developed by Aposense, targets apoptosis (programmed cell death) for molecular imaging and therapy. Eight tumors in seven patients demonstrated baseline images of pretreatment apoptosis, with ML-10 uptake increasing over time within the tumors compared with the nontarget tissue and blood. Following treatment, the signal in irradiated tumors increased nearly twofold, indicating a marked increase in the accumulation of ML-10 in tumors compared with other tissues.
Stay at the forefront of radiology with the Diagnostic Imaging newsletter, delivering the latest news, clinical insights, and imaging advancements for today’s radiologists.
Study Shows Enhanced Diagnosis of Coronary Artery Stenosis with Photon-Counting CTA
July 10th 2025In a new study comparing standard resolution and ultra-high resolution modes for patients undergoing coronary CTA with photon-counting detector CT, researchers found that segment-level sensitivity and accuracy rates for diagnosing coronary artery stenosis were consistently > 89.6 percent.
FDA Expands Approval of MRI-Guided Ultrasound Treatment for Patients with Parkinson’s Disease
July 9th 2025For patients with advanced Parkinson’s disease, the expanded FDA approval of the Exablate Neuro platform allows for the use of MRI-guided focused ultrasound in performing staged bilateral pallidothalamic tractotomy.